Cognition Therapeutics, Inc. - Common Stock (CGTX)
1.5400
+0.00 (0.00%)
NASDAQ · Last Trade: Sep 16th, 7:33 AM EDT
Detailed Quote
Previous Close
1.540
Open
-
Bid
1.540
Ask
1.580
Day's Range
N/A - N/A
52 Week Range
0.2223 - 3.830
Volume
82,206
Market Cap
100.04M
PE Ratio (TTM)
-2.299
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
8,042,451
Chart
About Cognition Therapeutics, Inc. - Common Stock (CGTX)
Cognition Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer’s disease and other forms of dementia. The company leverages its proprietary drug discovery platform to identify and advance small molecule therapeutics that target the underlying mechanisms of these conditions, aiming to improve cognitive function and enhance the quality of life for patients. By utilizing a unique approach that involves modulating cellular pathways associated with neurodegeneration, Cognition Therapeutics is dedicated to addressing significant unmet medical needs in the field of neurology. Read More
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an all-cash transaction
